Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Not Applicable

Completed

• Conditions: Stage I Prostate Cancer; Stage IIB Prostate Cancer; Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IIA Prostate Cancer
• Interventions: Radiation: stereotactic radiosurgery; Device: magnetic resonance imaging; Other: quality-of-life assessment; Procedure: Serum Prostate Antigen Test; Procedure: Digital Rectal Exam; Behavioral: Expanded Prostate Cancer Index Composite

• Registration Number: NCT02163317
• Lead Sponsor: Case Comprehensive Cancer Center

Brief Summary

This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed Description

PRIMARY OBJECTIVES:

I. Evaluate the correlation of histopathology findings in comparison to regions of the prostate reported to be suspicious for harboring tumor burden on multiparametric MRI report/s.

II. Demonstration of the dosimetric and radiobiological advantages of focal stereotactic body radiation therapy (SBRT) versus whole-gland radiation therapy.

III. Evaluation of clinical outcomes in focal SBRT for localized prostate cancer.

OUTLINE:

Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.

After completion of study treatment, patients are followed up every 3 months for up to 24 months.

Study Timeline

• Study First Submitted: 2014-06-11
• Study First Submitted QC: 2014-06-11
• Study First Posted: 2014-06-13
• Study Start: 2016-02-16
• Primary Completion: 2021-07-28
• Study Completion: 2021-07-28
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-08
• Last Update Posted: 2024-05-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

• Patients must have a histologically confirmed diagnosis of adenocarcinoma of the prostate
• Patient must have a history/physical examination with digital rectal examination of the prostate within 90 days prior to screening
• Eastern Cooperative Oncology Group (ECOG) performance status must be level 0 or 1 within 60 days prior to registration
• Patient must have a histological evaluation of the prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores ≤ 7(3+4)
• Serum creatinine ≤ 1.5 times upper limit of institutional normal (normal: ≤ 1.17 mL/min/1.73 m^2)
• Clinical stage a ≤ T1-T2a (American Joint Committee on Cancer [AJCC] 7th edition)
• Prostate specific antigen (PSA) ≤ 10 ng/mL within 90 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy
• Subjects must have the ability to understand and the willingness to sign a written informed consent document
• Patient willing and able to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire (baseline, 6, 12 and 24 months post end of radiation therapy)
• Patients must be able to undergo an MRI with contrast
• Bone scan completed within 90 days

Exclusion Criteria

• Evidence of distant metastases
• Regional lymph node involvement
• Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer
• Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
• Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol [DES]), or surgical castration (orchiectomy)
• Use of finasteride within 30 days prior to registration; PSA should not be obtained prior to 30 days after stopping finasteride
• Use of dutasteride within 90 days prior to registration; PSA should not be obtained prior to 90 days after stopping dutasteride
• Previous or concurrent cytotoxic chemotherapy for prostate cancer
• Severe, active co-morbidity, defined as follows:
• Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
• Transmural myocardial infarction within the last 6 months
• Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
• Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol; (patients on Coumadin or other blood thinning agents are eligible for this study)
• Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
• Patients unable to undergo an MRI with contrast

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (MRI-guided focal SRS)	stereotactic radiosurgery	Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
Treatment (MRI-guided focal SRS)	Expanded Prostate Cancer Index Composite	Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
Treatment (MRI-guided focal SRS)	quality-of-life assessment	Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
Treatment (MRI-guided focal SRS)	Digital Rectal Exam	Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
Treatment (MRI-guided focal SRS)	magnetic resonance imaging	Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
Treatment (MRI-guided focal SRS)	Serum Prostate Antigen Test	Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.

Primary Outcome Measures

Name	Time	Method
Number of patients with change in EPIC bowel domain score that was worse than 5 points	Up to 1 year from start of study	Number of patients with change in EPIC bowel domain score that was worse than 5 points; A rate for the worse-than-5 point change in bowel score of up to 35% of patients will be considered acceptable, with a rate ≥55% specified as unacceptable
Number of patients with change in EPIC urinary domain score that was worse than 2 points	Up to 1 year from start of study	Number of patients with change in EPIC urinary domain score that was worse than 2 points; A rate for the worse-than-2 point change in urinary score of up to 40% will be considered acceptable, with a rate ≥60% unacceptable

Secondary Outcome Measures

Name	Time	Method
Time to local progression	Up to 2 years from start of study	Radiographic efficacy will be summarized by calculating Kaplan-Meier curves. Descriptive reports of RECIST (1.1) and volumetric findings will be provided. Time will be reported in months.
PSA response	Up to 2 years from start of study	Number of patients with PSA failure. Failure occurs when the PSA is first noted to be 2 ng/mL or more than the patient's nadir value post radiation therapy completion
Number of acute gastrointestinal (GI) grade 3+ acute adverse events, evaluated by the Cancer Therapy Evaluation Program (CTEP) active version of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)	Up to 30 days after the completion of radiation therapy	Defined as the first occurrence of worst severity of the adverse event =\< 30 days after the completion of radiation therapy. Multivariate analysis will be used, and acute rates of GI toxicity will be reported with dose-volume histogram.
Number of late GU grade 3+ acute adverse events, evaluated by the CTEP version of the NCI CTCAE	Up to 2 years from start of study	Defined as the first occurrence of worst severity of adverse event \> 180 days after radiation therapy completion.
Number of patients with Disease-free survival	Up to 2 years from start of study	Defined as From the date of treatment to the date of documentation of disease progression or until the date of death from any cause. Radiographic efficacy will be summarized by calculating Kaplan-Meier curves. Also, 95% confidence intervals will be reported. Descriptive reports of Response Evaluation Criteria in Solid Tumors (RECIST) (1.1) and volumetric findings will be provided.
Time to distant failure	Up to 2 years from start of study	Radiographic efficacy will be summarized by calculating Kaplan-Meier curves. Descriptive reports of RECIST (1.1) and volumetric findings will be provided. Time will be reported in months.
Number of acute genitourinary (GU) grade 3+ acute adverse events, evaluated by the CTEP version of the NCI CTCAE	Up to 2 years from start of study	Defined as the first occurrence of worst severity of the adverse event =\< 30 days after the completion of radiation therapy.
Number of late GI grade 3+ acute adverse events, evaluated by the CTEP version of the NCI CTCAE	Up to 2 years from start of study	Defined as the first occurrence of worst severity of adverse event \> 180 days after radiation therapy completion. Multivariate analysis will be used, and acute rates of GI toxicity will be reported with dose-volume histogram.

Trial Locations

Locations (1)

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center; 🇺🇸 Cleveland, Ohio, United States